UroGen Submits NDA for UGN-103 Bladder Cancer Treatment
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
WASHINGTON, May 14, 2026 Johnson & Johnson released findings from a groundbreaking global survey revealing the significant physical, emotional,...
